Replimune/REPL

$6.50

1.25%
-
1D1W1MYTD1YMAX

About Replimune

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Ticker

REPL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Philip Astley-Sparke

Employees

284

Headquarters

Woburn, United States

Replimune Metrics

BasicAdvanced
$395.95M
Market cap
-
P/E ratio
-$3.16
EPS
1.26
Beta
-
Dividend rate
$395.95M
1.25667
$24.81
$5.89
1.32M
12.398
16.13
16.77
-34.66%
-41.29%
-36.63%
0.939
0.939
-10.71%

What the Analysts think about Replimune

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
108.62% upside
High $19.00
Low $10.00
$6.50
Current price
$13.56
Average price target

Replimune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
-
Net income
$-51.1M
-14.83%
Profit margin
0%
-

Replimune Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.99%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.74
-$0.75
-$0.90
-$0.77
-
Expected
-$0.67
-$0.84
-$0.86
-$0.93
-$0.79
Surprise
9.83%
-11.14%
5.18%
-16.99%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Replimune stock?

Replimune (REPL) has a market cap of $395.95M as of April 24, 2024.

What is the P/E ratio for Replimune stock?

The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of April 24, 2024.

Does Replimune stock pay dividends?

No, Replimune (REPL) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Replimune dividend payment date?

Replimune (REPL) stock does not pay dividends to its shareholders.

What is the beta indicator for Replimune?

Replimune (REPL) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Replimune stock price target?

The target price for Replimune (REPL) stock is $13.56, which is 111.21% above the current price of $6.42. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Replimune stock

Buy or sell Replimune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing